Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang, Zhe Liu, Xi Chen, Mengzhao Wang, Shiying Yu, Helong Zhang, Jian Fang, Wei Li, Chih-Hsin Yang, Gee-Chen Chang, Te-Chun Hsia, Cheng-Ta Yang, Chin-Chou Wang, Byoung Chul Cho, Ki Hyeong Lee, Young-Chul Kim, Ho Jung An, In Sook Woo, Jae Yong Cho, Sang Won Shin, Jong-Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles Blanco, Martin Emilio Lazaro Quintela, Enriqueta Felip Font, Anne-Marie Dingemans, Lynne Bui
Publikováno v:
The Lancet Respiratory Medicine. 8:1132-1143
Summary Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexp
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Filippo de Marinis, Cesare Gridelli, Maria Chiara Garassino, Francesco Grossi, Antonio Rossi, Adolfo Favaretto, Editta Baldini, Maria Rita Migliorino, Paolo A. Ascierto, Alessandro Morabito
Publikováno v:
Current Clinical Pharmacology. 13:76-84
Background: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approv
Autor:
Letizia Gianoncelli, Marcello Tiseo, Paolo Pedrazzoli, Antonio Maconi, Federico Cappuzzo, Stefano Frega, Maria Pagano, Giulia Pasello, Matteo Perrino, F. Zanelli, Maria Bonomi, Carmine Pinto, Filippo de Marinis, Luca Boni, Federica Grosso, Armando Santoro, Candida Bonelli, Marina Chiara Garassino, Paolo Andrea Zucali, Francesco Grossi, Giovanni Luca Ceresoli, Erika Gervasi, Hector Soto Parra
Summary Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78597edc6a57d0d326a538c014d92e8a
http://hdl.handle.net/11383/2125715
http://hdl.handle.net/11383/2125715
Autor:
Letizia Gianoncelli, Antonio Passaro, Ilaria Attili, Chiara Catania, Giuseppe Curigliano, Valeria Stati, Stefania Morganti, Ester Del Signore, Gianluca Spitaleri, Filippo de Marinis
Publikováno v:
Cancer treatment reviews. 89
Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patient
Autor:
Alberto Pavan, Filippo de Marinis, Laura Bonanno, Antonio Passaro, Ilaria Attili, Pierfranco Conte
Publikováno v:
Critical Reviews in Oncology/Hematology. 119:30-39
Immune checkpoint inhibitors (ICIs) have emerged as one of the main new therapeutic options for advanced non-small cell lung cancer (NSCLC) patients. Even though they demonstrated superiority towards standard chemotherapy in different disease setting
Autor:
Domenico Amoroso, Alessandro Bertolini, Maria Rita Migliorino, Andrea Luciani, Adolfo Favaretto, Alba A. Brandes, Paolo Bidoli, Giuseppe Tonini, Cesare Gridelli, Filippo de Marinis
Publikováno v:
Anticancer Research. 37:2457-2464
Background/aim The management of elderly patients with advanced non-squamous NSCLC includes several strategies. Patients and methods Patients (≥70 years) were randomly assigned to bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2
Autor:
Antonio Rossi, Francesco Perrone, Filippo de Marinis, Fortunato Ciardiello, Agnese Montanino, Cesare Gridelli, Floriana Morgillo, Nicola Normanno, Ciro Gallo, Gennaro Daniele, Lucio Crinò, Maria Carmela Piccirillo, Alessandro Morabito
Publikováno v:
Clinical Lung Cancer. 17:461-465
BACKGROUND: About 20% of advanced non-small-cell lung cancer (NSCLC) cases harbor somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene. In these patients, the standard first-line treatments are the EGFR-
Autor:
Silvia Novello, Françoise Mornex, Rafal Dziadiuszko, Martin Früh, Enriqueta Felip, Federico Cappuzzo, Markus Glatzer, Corinne Faivre-Finn, Fiona H Blackhall, Ben J. Slotman, Mary O’ Brien, Dirk De Ruysscher, Esther G.C. Troost, Paul Van Houtte, Stéphanie Peeters, José Belderbos, Benjamin Besse, Sara Ramella, Fiona McDonald, Paul Martin Putora, Martin Reck, Pilar Garrido, Cécile Le Péchoux, Filippo de Marinis, Virginie Westeel, Ursula Nestle, Raffaele Califano, Joachim Widder, Christoph Pöttgen, L. Arés
Publikováno v:
Radiotherapy and Oncology, 135, 74-77. Elsevier Ireland Ltd
Radiotherapy and Oncology 135(2019), 74-77
Putora, P M, Glatzer, M, de Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien, M O, Paz Ares, L, Peeters, S, Pöttgen, S, Ramella, S, Reck, M, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & Slotman, B J 2019, ' Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 135, pp. 74-77 . https://doi.org/10.1016/j.radonc.2019.02.010
Radiotherapy and Oncology 135(2019), 74-77
Putora, P M, Glatzer, M, de Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien, M O, Paz Ares, L, Peeters, S, Pöttgen, S, Ramella, S, Reck, M, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & Slotman, B J 2019, ' Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 135, pp. 74-77 . https://doi.org/10.1016/j.radonc.2019.02.010
Background: The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted.Methods: We obtained a list of 13 European medical oncologists from the International Association for the Study of L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9e8d893418515be78de97bf8a595780
http://hdl.handle.net/2318/1694881
http://hdl.handle.net/2318/1694881